Ori Biotech Raises $9.4M in Seed Funding


Ori Biotech Ltd, a a London- and Philadelphia-based Cell and Gene Therapy (CGT) manufacturing company, closed a $9.4M (£7M) seed funding round.

Backers included Amadeus Capital Partners, Delin Ventures, Kindred Capital and a London-based family office, alongside a group of angel investors.

The company intends to use the funds to bring their manufacturing platform to market.

Founded by Dr. Farlan Veraitch and Prof. Chris Mason in 2015 and led by newly appointed CEO Jason C. Foster, Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.



Join the discussion